Log In
BCIQ
Print this Print this
 

Fosfomycin: Tobramycin for inhalation, FTI, fosfomycin/tobramycin (formerly GS 9310/11)

  Manage Alerts
Collapse Summary General Information
Company Gilead Sciences Inc.
DescriptionInhaled co-formulation of fosfomycin and tobramycin
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentPhase II
Standard IndicationPseudomonas
Indication DetailsTreat Pseudomonas aeruginosa lung infection in cystic fibrosis (CF) patients
Regulatory Designation
PartnerCURx Pharmaceuticals Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

02/24/2014

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today